Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) (CAT#: BSIG-132)
Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD89 and anti-EGFR parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-132). Click the button below to contact us or submit your feedback about this product.